Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 17/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013229 | 1.00 | NTRK1 (0.49) | NTRK1PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL19180711 | 0.92 | PDE4B (0.46) | NTRK1PDE4BKMT2AL3MBTL1 | |
| SCHEMBL2016338 | 0.92 | PDE4B (0.46) | NTRK1PDE4BKMT2AL3MBTL1 | |
| SCHEMBL1975870 | 0.92 | PDE4B (0.46) | NTRK1PDE4BKMT2AL3MBTL1 | |
| SCHEMBL23369466 | 0.88 | NTRK1 (0.49) | NTRK1PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL21622314 | 0.88 | NTRK1 (0.49) | NTRK1PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL21936207 | 0.88 | KMT2A (0.47) | NTRK1PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL1986245 | 0.88 | KMT2A (0.48) | PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL2012023 | 0.88 | KMT2A (0.48) | PDE4BKMT2AL3MBTL1SIGMAR1 | |
| SCHEMBL16780873 | 0.88 | KMT2A (0.52) | NTRK1PDE4BKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346786-B2 | Pyrrolidine compounds | HOFFMANN-LA ROCHE INC. (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| EP-2513084-B1 | PYRROLIDINE DERIVATIVES AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2513084-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
| WO-2011073160-A1 | PYRROLIDINE DERIVATIVES AS NK - 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203728-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | NTRK1 204/4885PDE4B 529/4885KMT2A 1681/4885 |
| US-20110152233-A1 | PYRROLIDINE COMPOUNDS | SLC6A3, OPRL1, OPRK1 | NTRK1 204/4885PDE4B 529/4885KMT2A 1681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.